Efficacy of decentralised home-based antihypertensive treatment in older adults with multimorbidity and polypharmacy (ATEMPT): an open-label randomised controlled pilot trial
2024

Home Treatment for High Blood Pressure in Older Adults

Sample size: 230 publication 10 minutes Evidence: moderate

Author Information

Author(s): Majert Jeannette MD, Nazarzadeh Milad DPhil, Ramakrishnan Rema PhD, Bidel Zeinab MSc, Hedgecott Deborah BSc, Perez-Crespillo Abel MBA, Turpie Wendy PhD, Akhtar Naseem BSc, Allison Moira BSc, Rao Shishir DPhil, Gudgin Bernard PhD, McAuley Melanie, A'Court Christine MRCP, Billot Laurent Prof MSc, Kotecha Dipak Prof PhD, Potter John Prof FRCP, Rahimi Kazem Prof FRCP

Primary Institution: University of Oxford

Hypothesis

Can different intensities of antihypertensive treatment effectively lower blood pressure in older adults with multiple health issues?

Conclusion

Decentralised antihypertensive treatment significantly reduced blood pressure in older adults without increasing serious adverse events.

Supporting Evidence

  • Blood pressure decreased from 134.5 mm Hg to 122.1 mm Hg in the more medication group.
  • No cardiovascular events occurred in the more medication group.
  • Participants reported high satisfaction with the remote trial design.
  • Serious adverse events were similar across both treatment groups.
  • Participants in the more medication group reported more dizziness and fatigue.

Takeaway

This study shows that giving more blood pressure medicine to older people can help lower their blood pressure without making them feel worse.

Methodology

A two-armed, parallel-group, open-label randomised controlled pilot trial conducted remotely with participants aged 65 and older.

Potential Biases

Open-label design may have influenced reporting of side effects.

Limitations

The study had a relatively short follow-up period and was not powered to detect modest differences in safety outcomes.

Participant Demographics

Mean age was 76 years, with 51% women and 80% having three to five comorbidities.

Statistical Information

P-Value

p=0.97

Confidence Interval

95% CI –17.5 to –4.0

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/S2666-7568(23)00259-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication